Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Annexon (Nasdaq: ANNX) granted an inducement option to a new non-executive employee under its 2022 Employment Inducement Award Plan.

The board approved the award on March 12, 2026; the option to buy 20,000 shares was granted at a $5.66 exercise price on March 13, 2026, carries a ten-year term and vests over four years (25% at year one, then monthly 1/48th).

Key Figures

Target population: 10 million people Plan year: 2022 Option shares: 20,000 shares +5 more

8 metrics

Target population 10 million people Neuroinflammatory diseases worldwide impacted

Plan year 2022 Employment Inducement Award Plan

Option shares 20,000 shares Inducement option grant to new non-executive employee

Exercise price $5.66 per share Option strike set at March 13, 2026 closing price

Option term 10 years Duration of inducement stock option

Vesting period 4 years Overall vesting schedule for the option grant

Initial vesting 25% Portion vesting on first anniversary of grant date

Ongoing vesting 1/48th monthly Monthly vesting after first anniversary

Market Reality Check

Price: $5.60 Vol: Volume 702,704 is below 2...

low vol

$5.60 Last Close

Volume Volume 702,704 is below 20-day average of 2,548,166 (relative volume 0.28x). low

Technical Price at $5.65 is trading above the 200-day MA of $3.71.

Peers on Argus

ANNX was up 3.71% pre-news while peers showed mixed moves (e.g., NMRA -1.32%, AL...

ANNX was up 3.71% pre-news while peers showed mixed moves (e.g., NMRA -1.32%, ALEC -3.93%, LCTX +1.9%), indicating stock-specific factors rather than a broad sector move.

Historical Context

5 past events · Latest: Feb 24 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 24	Conference presentation	Neutral	+1.4%	TD Cowen healthcare conference presentation announcement with webcast details.
Feb 17	KOL event announcement	Positive	+3.1%	KOL event to discuss vonaprument and Phase 3 ARCHER II timeline.
Jan 16	Inducement grants	Neutral	+1.5%	Inducement equity awards of 155,000 options to two new employees.
Jan 12	Pipeline strategy update	Positive	+5.9%	Outlined 2026 registrational milestones and cash runway into late 2027.
Jan 08	MAA submission	Positive	-4.3%	Filed MAA to EMA for tanruprubart in Guillain-Barré syndrome.

Pattern Detected

Recent company news has more often seen positive price reactions, with only the Guillain-Barré MAA headline followed by a negative move.

Recent Company History

Over recent months, Annexon has issued a series of pipeline and corporate updates. A January 8 MAA submission for tanruprubart in GBS was followed by broader 2026 milestone guidance on Jan 12, which saw the strongest gain at +5.9%. Subsequent items included inducement grants and conference/KOL event announcements, each followed by modestly positive moves between +1.43% and +3.07%. Today’s small inducement option grant fits into this pattern of routine corporate updates.

Market Pulse Summary

This announcement details a standard inducement equity award: an option to purchase 20,000 shares at...

Analysis

This announcement details a standard inducement equity award: an option to purchase 20,000 shares at $5.66 with a 10-year term and 4-year vesting under Nasdaq Listing Rule 5635(c)(4). It follows several recent operational and pipeline updates that often coincided with modestly positive price moves. Investors may contextualize this routine grant alongside prior news on registrational milestones, cash runway, and regulatory filings when monitoring future company developments.

Key Terms

nasdaq listing rule 5635(c)(4), exercise price, vesting

3 terms

nasdaq listing rule 5635(c)(4) regulatory

"granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on March 12, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

exercise price financial

"The option carries a ten-year term and an exercise price per share equal to $5.66, which was the closing price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"and vests over 4 years, with 25% of the shares underlying the options vesting on the first anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. Not financial advice.

BRISBANE, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on March 12, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

The new non-executive employee received an option to purchase 20,000 shares of Annexon common stock. The option carries a ten-year term and an exercise price per share equal to $5.66, which was the closing price of Annexon’s common stock on March 13, 2026, the date of grant, and vests over 4 years, with 25% of the shares underlying the options vesting on the first anniversary of the grant date and an additional 1/48th of the shares vesting monthly thereafter, subject to continued service through the applicable vesting dates.

About Annexon

Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.

Investor Contact:

Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com

FAQ

What equity inducement did Annexon (ANNX) approve on March 12, 2026?

Annexon approved an inducement option for a new non-executive employee to purchase 20,000 shares. According to the company, the option was approved March 12, 2026 and granted with an exercise price equal to the closing stock price on March 13, 2026.

What are the key terms of the Annexon (ANNX) option grant dated March 13, 2026?

The option covers 20,000 shares, has a ten-year term, and vests over four years. According to the company, the exercise price was $5.66, equal to Annexon’s March 13, 2026 closing price, with 25% vesting after one year and monthly thereafter.

How does the Annexon (ANNX) option vesting schedule work for the new hire?

The option vests 25% after one year, then 1/48th monthly for the remaining three years. According to the company, continued service through each vesting date is required and the full schedule spans four years from the grant date.

Why was the Annexon (ANNX) equity grant made under Nasdaq Listing Rule 5635(c)(4)?

The grant was an inducement for a newly hired employee and followed Nasdaq rules for such awards outside existing shareholder approvals. According to the company, the award was made under Rule 5635(c)(4) and approved March 12, 2026.

What exercise price was set for the Annexon (ANNX) option and how was it determined?

The exercise price was set at $5.66 per share, equal to the closing price on March 13, 2026. According to the company, the exercise price matches Annexon’s market close on the grant date and applies for the ten-year option term.